Sensor Patch Market to Reach US$ 28.9 Bn by 2031, Growing at 29.6% CAGR as Continuous Glucose and Cardiac Monitoring Expand: Wissen Research

Wissen Research estimates the global sensor patch market at USD 7.9 billion in 2026 and projects it will reach USD 28.9 billion by 2031, a 29.6% CAGR. Growth is supported by rising chronic disease monitoring, remote care, longer-wear devices, and expanding glucose and cardiac applications, although accuracy, validation, comfort, and data governance remain challenges. Recent developments include Abbott’s CE Mark approval for glucose-ketone wearables, DexCom’s FDA clearance to extend Stelo to children aged 2 and older who do not use insulin, and iRhythm’s agreement to acquire VitalConnect for approximately USD 287.5 million.

Analysis

The investable signal is not the market-size forecast; it is whether incumbent device makers can turn regulatory clearance and broader eligibility into durable, reimbursed usage. The report’s wide category definition and promotional source make its 29.6% CAGR a poor basis for revenue or valuation assumptions. Near term, treat new product clearances as adoption options, not earnings catalysts until utilization, payer coverage, and repeat wear are visible.

Abbott (ABT) and DexCom (DXCM) have the clearest opportunity to expand addressable users, but longer-wear sensors create a unit-economics tension: fewer replacements per patient could be offset by better adherence and more users. The key read-through is net revenue per active user, not headline eligibility. In cardiac monitoring, iRhythm (IRTC)’s proposed VitalConnect acquisition could add hospital and remote-care reach, but also introduces integration and execution risk; deal terms and realized cross-selling matter more than the strategic rationale. Emerging multimodal and biochemical patches are a longer-dated threat and opportunity, not yet a basis for assuming commercial scale given the validation and accuracy hurdles described.

Over 1–3 months, watch launches, coverage decisions, and company disclosures on active users, retention, and sensor wear economics. Over 6–18 months, broader use could reinforce recurring data and monitoring ecosystems, while reimbursement limits or accuracy/adhesion problems would constrain adoption. Contrarian point: strong category growth can coexist with weak shareholder returns if competition, replacement frequency, or clinical-validation costs absorb the value. The thesis weakens if user growth fails to translate into recurring revenue, or if IRTC’s acquisition fails to close or deliver measurable commercial uptake.

Key Decisions for Investors

• Do not buy a sensor-patch basket on the market forecast alone. Treat it as a thematic screen; the forecast’s category scope and underlying methodology need independent validation.
• Keep ABT and DXCM on an adoption watchlist rather than making a directional pair trade from clearance news alone. Reassess after disclosures on active-user growth, retention, payer coverage, and revenue per user; those metrics test whether broader access offsets lower replacement frequency.
• For IRTC, monitor the VitalConnect transaction as an execution event, not an automatic synergy trade. Verify closing status, integration costs, and evidence of cross-selling before underwriting incremental earnings.
• Falsifiers: weaker-than-expected user or revenue growth despite expanded eligibility; deteriorating retention or wear performance; restrictive reimbursement decisions; or failure to show commercial traction in IRTC’s expanded offering.